Floatz logo

Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Nivolumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BBB (72)
Nivolumab
Urethra Transitional Cell Carcinoma
Nagoya UniversityP3BBB (72)
Nivolumab
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3BBB (72)
Nivolumab
Uveal Melanoma
Inge Marie SvaneP3BBB (72)
Nivolumab
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP3BBB (72)
Nivolumab
Sarcomatoid Renal Cell Carcinoma
City of Hope Medical CenterP3BBB (72)
Nogitecan
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P3BBB (72)
Omeprazole
Breast Cancer
Genentech, Inc.P3BBB (72)
Oxaliplatin
Chemotherapy-Induced Toxicity
Linhui PengP3BBB (72)
Oxaliplatin
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Palifermin
Lymphoma
Center for International Blood and Marrow Transplant ResearchP3BBB (72)
Pegargiminase
Hepatocellular Carcinoma
Chang Gung Memorial HospitalP3BBB (72)
Pembrolizumab
Acute Myeloid Leukemia
Joanna YiP3BBB (72)
Pembrolizumab
Brain Neoplasm
Essen BiotechP3BBB (72)
Pembrolizumab
Breast Cancer
West German Study GroupP3BBB (72)
Pembrolizumab
Breast Neoplasm
Merck Sharp & Dohme LLCP3BBB (72)
Pembrolizumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)P3BBB (72)
Pembrolizumab
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3BBB (72)
Pembrolizumab
Cutaneous Melanoma
Melanoma Institute AustraliaP3BBB (72)
Pembrolizumab
Endometrial Carcinoma
Eikon TherapeuticsP3BBB (72)
Pembrolizumab
Ovarian Carcinoma
Roswell Park Cancer InstituteP3BBB (72)
Pembrolizumab
Esophageal Squamous Cell Carcinoma
GV20 TherapeuticsP3BBB (72)
Pembrolizumab
Breast Carcinoma
The Netherlands Cancer InstituteP3BBB (72)
Pembrolizumab
Metastatic Melanoma
Brown UniversityP3BBB (72)
Showing 2701 to 2725 of 42,289 assets
PreviousPage 109 of 1692Next